Figure 4From: Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients Pharmacological activity of DIMS0150. In the explorative phase IIa study, whole blood was collected before and 4Â hrs after DIMS0150 treatment and the levels of IP-10 mRNA measured through qPCR. The P-value was calculated between placebo and DIMS0150 treated group using unpaired t-test.Back to article page